• Ariad Pharmaceuticals Inc., of Cambridge, Mass., completed its previously announced public offering of 24.7 million common shares, including overallotment, priced at $10.42 each, for gross proceeds of $257 million. Net proceeds of $243 million will support pivotal trial follow-up and approval filings for leukemia drug ponatinib. (See BioWorld Today, Dec. 16, 2011.)